Buchumschlag

Progression‐Free Survival Prediction Performance of ChatGPT: Analysis With Real Life Data in Early and Locally Advanced Prostate Cancer

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Engin Eren Kavak, İsmail Dilli
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2025
Schlagworte:	The Prostate
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Survival Outcomes for Rural Patients With Advanced Prostate Cancer: A SEER Investigation
von: Liang G. Qu, et al.
Veröffentlicht: (2025)

Towards Precision Oncology: A New Predictive Machine Learning Model for Early Progression to Castration Resistant Prostate Cancer
von: Miguel Ángel Gómez‐Luque, et al.
Veröffentlicht: (2025)

Prostate‐Specific Antigen Response at Six Months Predicts Progression in Metastatic Hormone‐Sensitive Prostate Cancer Treated With Apalutamide
von: Christian Andrés Martínez Osorio, et al.
Veröffentlicht: (2025)

Impact of Genomic Mutations on the Transcriptional Pathways and Tumor Microenvironment Landscape of Localized Early Prostate Cancer
von: William Lautert‐Dutra, et al.
Veröffentlicht: (2026)

Factors Associated With Male Breast Cancer Incidence Among Prostate Cancer Survivors: Real World Evidence From Veterans Affairs National Prostate Cancer Data Core
von: Erum Z. Whyne, et al.
Veröffentlicht: (2025)

Real‐World Overall Survival Comparison of Enzalutamide and Abiraterone In First‐ and Second‐Line Setting of Metastatic Castration‐Resistant Prostate Cancer
von: András Horváth, et al.
Veröffentlicht: (2025)

The Prognostic Value of the Prostate Adenocarcinoma With Ductal Feature in Patients With Advanced Prostate Cancer Treated With Abiraterone Acetate
von: Yifu Shi, et al.
Veröffentlicht: (2025)

Number of Prescription Medications and Overall Survival in Metastatic Castrate‐Resistant Prostate Cancer
von: Carley R. Pickett, et al.
Veröffentlicht: (2024)

Perioperative Safety and Early Oncologic Outcomes of Salvage Irreversible Electroporation for Radiorecurrent Prostate Cancer
von: Jarrett Noakes, et al.
Veröffentlicht: (2026)

Association of Weight Loss and BMI on PSA Levels and Overall Survival in Veterans With Metastatic Castrate‐Resistant Prostate Cancer
von: Nicholas Fedele, et al.
Veröffentlicht: (2025)

Prognostic Nutritional Index as a Biomarker in Metastatic Hormone‐Sensitive Prostate Cancer: Impact on Survival and Treatment Optimization
von: Muhammet Bekir Hacioglu, et al.
Veröffentlicht: (2025)

Impact of Testosterone Recovery on Oncologic Outcomes in High‐Risk, Localized Prostate Cancer
von: Trevor C. Hunt, et al.
Veröffentlicht: (2025)

Second Therapeutic Freeze After Salvage Cryoablation for Localized Radiorecurrent Prostate Cancer
von: Sudharshanan Balaji, et al.
Veröffentlicht: (2026)

Prostate Specific Antigen Density and Clinically‐Significant Prostate Cancer: The Influence of Prostatic Volume
von: Elizabeth Robinson, et al.
Veröffentlicht: (2025)

Comprehensive Analysis of Fraction of Genome Altered in Prostate Cancer Treatment
von: Muhammad Umair, et al.
Veröffentlicht: (2026)

USPSTF Recommendation Against PSA Screening vs. Stage and Cancer‐Specific Mortality in Localized Prostate Cancer
von: Fabian Falkenbach, et al.
Veröffentlicht: (2025)

Socioeconomic and Demographic Factors in Genetic Testing Utilization Among Advanced Prostate Cancer Patients
von: Alexandra T. Skowron, et al.
Veröffentlicht: (2026)

The Diagnostic Value of Plasma Small Extracellular Vesicle‐Derived CAIX Protein in Prostate Cancer and Clinically Significant Prostate Cancer: A Study on Predictive Models
von: Haotian Chen, et al.
Veröffentlicht: (2025)

Prostate Volume and PSA‐Density Estimation by Transabdominal Ultrasound: Prospective Evidence of Comparative Accuracy to MRI and Transrectal Ultrasound in Prostate Cancer Early Diagnostics
von: Liza M. Kurucz, et al.
Veröffentlicht: (2025)

Transcriptomic Signatures of Monocyte‐Derived Macrophages Associate With Androgen Receptor Pathway Inhibitor Progression in Prostate Cancer
von: Marina Nasrin Sharifi, et al.
Veröffentlicht: (2025)

Genetic Testing Among Black and White Patients With Advanced Prostate Cancer: A Retrospective Analysis of Testing Utilization and Referral Patterns
von: Kyle C. McElyea, et al.
Veröffentlicht: (2025)

Effect of Marital Status on Years of Life Lost From Metastatic Prostate Cancer According to Race/Ethnicity
von: Leonardo Quarta, et al.
Veröffentlicht: (2026)

The Prognostic Significance of Radiographic Progression Without PSA Progression in Patients With Metastatic Hormone‐Sensitive Prostate Cancer Treated With First‐Line ARPI Therapy
von: Takeshi Tsutsumi, et al.
Veröffentlicht: (2026)

Assessment of Circulating Neuroendocrine Tumor Markers at Prostate Cancer Diagnosis: An Investigation of Prostate Cancer With Neuroendocrine Features
von: Tatsuya Shimomura, et al.
Veröffentlicht: (2026)

Evidence and Rationale for Prostate Cancer Screening
von: Takeshi Takahashi
Veröffentlicht: (2025)

Long‐Term Oncological Outcomes of Robot‐Assisted Radical Prostatectomy for Clinically Localized Grade Groups 4 and 5 Prostate Cancers Diagnosed on Prostate Biopsy
von: Victor Sandoval, et al.
Veröffentlicht: (2025)

Immunohistochemical Analysis of Androgen Receptor Expression Predicts the Prognosis of Metastatic Castration‐Sensitive Prostate Cancer Patients Receiving Abiraterone Acetate
von: Mitsuhisa Nishimoto, et al.
Veröffentlicht: (2025)

Efficacy and Predictive Factors Analysis of Androgen Deprivation Plus Novel Hormone Therapy as Neoadjuvant Treatment for High‐Risk Prostate Cancer
von: Hanyang Tao, et al.
Veröffentlicht: (2024)

pSTAT3 Expression is Increased in Advanced Prostate Cancer in Post‐Initiation of Androgen Deprivation Therapy
von: Piotr Bialas, et al.
Veröffentlicht: (2024)

Life Expectancy in High‐Grade Incidental Prostate Cancer Patients Versus Population‐Based Controls According to Treatment Type
von: Francesco Di Bello, et al.
Veröffentlicht: (2024)

Prognostic Impact of Initial Prostate Specific Antigen Half‐Life After Abiraterone Acetate in High‐Volume Metastatic Hormone‐Sensitive Prostate Cancer: Who May Need Triplet Therapy?
von: Kotaro Suzuki, et al.
Veröffentlicht: (2026)

Altered Glycosylation of PSA in Prostate Cancer Tissue
von: Hannu Koistinen, et al.
Veröffentlicht: (2025)

Castration Resistance Accelerates Prostate Cancer Kinetics
von: Sheila Jonnatan, et al.
Veröffentlicht: (2026)

CHARGE: The “Big Questions” in Prostate Cancer for 2024
von: Andrea K. Miyahira, et al.
Veröffentlicht: (2024)

Bone Metastasis Distribution Matters: Prognostic Effect of the Axial‐to‐Peripheral Ratio in Metastatic Hormone‐Sensitive Prostate Cancer
von: Ali Fuat Gürbüz, et al.
Veröffentlicht: (2026)

Efficacy and Feasibility of Cabazitaxel for Very Elderly Patients of ≥ 80 Years of Age With Metastatic Castration‐Resistant Prostate Cancer: A Real‐World Multi‐Intuitional Analysis
von: Kotaro Suzuki, et al.
Veröffentlicht: (2025)

Genomic and Clinical Impact of Smoking on Therapeutic Outcomes in Prostate Cancer: A Public Databases Analysis
von: Tomoya Hatayama, et al.
Veröffentlicht: (2026)

Effects of Concurrent Administration of Spironolactone in Veterans with Metastatic Prostate Cancer Receiving Abiraterone: A Real‐World Retrospective Study
von: Erum Z. Whyne, et al.
Veröffentlicht: (2024)

Developments in Ultrasound‐Based Imaging for Prostate Cancer Detection
von: Reid Vassallo, et al.
Veröffentlicht: (2025)

Long‐Term Follow‐Up of Neoadjuvant Enzalutamide Plus Androgen Deprivation Therapy in Localized Prostate Cancer: A Secondary Analysis of a Neoadjuvant Feasibility Trial
von: Braden Millan, et al.
Veröffentlicht: (2025)